Clinical trials · Houston, TX
Advanced Renal Cell Carcinoma clinical trials in Houston
We’re tracking 60 recruiting advanced renal cell carcinoma studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06708949RecruitingPhase 2
Immunotherapy combo for advanced kidney cancer
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Houston, TexasAges 18 years+ - NCT06053658RecruitingPhase 2
Tivozanib and Nivolumab for advanced kidney cancer
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Houston, TexasAges 18 years+ - NCT06444880RecruitingPhase 2
Testing ubamatamab for MUC16-positive rare cancers
This study tests a new drug, ubamatamab, alone or with another drug called cemiplimab, for people with rare cancers like renal medullary carcinoma or epithelioid sarcoma. These drugs help your immune system attack cancer cells that have a specific protein (MUC16).
Houston, TexasAges 12 years+ - NCT07227870RecruitingPhase 2
Study of L19IL2/TNF for advanced basal cell carcinoma
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
Houston, TexasAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
New drug for NSCLC with EGFR or HER2 mutations
This trial tests a new medication, BH-30643, for people with non-small cell lung cancer that has spread and has specific EGFR or HER2 gene changes. The goal is to see if this treatment can shrink tumors after other standard therapies have been tried.
Houston, TexasAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Houston, TexasAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Houston, TexasAges 18–80 - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Houston, TexasAges 18 years+ - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Houston, TexasAges 18 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Houston, TexasAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Houston, TexasAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Houston, TexasAges 18 years+ - NCT05287945RecruitingPhase 1/Phase 2
Orellanine for kidney cancer patients on dialysis
This early-stage study tests orellanine to treat advanced kidney cancer that has spread (metastatic clear-cell or papillary type). It may help by shrinking or controlling cancer, and by seeing whether the treatment is safe and tolerable in people already on chronic dialysis.
Houston, TexasAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Houston, TexasAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Houston, TexasAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Houston, TexasAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Houston, TexasAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
Houston, TexasAges 12 years+ - NCT05010109Recruiting
Testing heart safety and fitness during lung cancer chemoradiation
This study looks at how lung cancer treatment affects the heart and whether a “walking test” and blood tests can track heart fitness and injury. It may help by improving how cancer therapy is planned and monitored for heart safety.
Houston, TexasAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
Houston, TexasAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+
Hear when a new Advanced Renal Cell Carcinoma trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
Advanced Renal Cell Carcinoma trials in other cities
Where these studies are running near Houston
Institutions with a site for the recruiting advanced renal cell carcinoma studies listed above.
- The University of Texas MD Anderson Cancer Center · 19 studies
- Houston Methodist Hospital
- Millennium Physicians
- NEO-811 Houston Site
- Oncology Consultants
- Research Site
- The University of Texas MD Anderson Cancer Center - League City
- The University of Texas MD Anderson Cancer Center - Sugar Land
What taking part in a advanced renal cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced renal cell carcinoma studies in Texas.
Common questions
- Are there advanced renal cell carcinoma clinical trials near Houston?
- Yes. We're currently tracking 60 recruiting advanced renal cell carcinoma studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced renal cell carcinoma study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced renal cell carcinoma studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.